Antigenics, Inc. ATGC

Company Overview

Antigenics, Inc. (NASDAQ: ANTI) was a biotechnology company focused on the discovery, development, and commercialization of immunotherapies and vaccine technologies for cancer and infectious diseases. The company operated primarily within the biotechnology and biopharmaceutical industries, with a strategic emphasis on heat shock protein–based therapeutics, personalized cancer vaccines, and immune system modulation technologies. Antigenics generated value through clinical-stage product development, licensing arrangements, collaborative research agreements, and proprietary technology platforms. Its principal customer and stakeholder base included healthcare providers, research institutions, pharmaceutical collaborators, and oncology-focused clinical networks.

The company was founded in 1994 and became known for developing therapeutic vaccine candidates targeting oncology indications. One of its most recognized programs was Oncophage, an autologous cancer vaccine utilizing heat shock protein technology. Over time, Antigenics expanded its immuno-oncology capabilities through internal research and strategic acquisitions. In January 2011, the company formally changed its corporate name from Antigenics, Inc. to Agenus Inc. to reflect a broader immunotherapy-focused strategy and evolving pipeline. Public filings and company disclosures indicate that the transition represented both a branding and strategic repositioning toward checkpoint antibodies, adjuvant technologies, and broader immuno-oncology development.